ArticleAmerican journal of cancer research2025
Thyroid hormone suppresses cell growth by regulating CDK2 and cyclin E1 expression via Hepsin.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid hormone (T3) and its receptor (TR) play crucial roles in regulating cell proliferation and cancer progression, including hepatocellular carcinoma (HCC). However, the specific mechanisms underlying HCC development mediated by T3/TR remain unclear. This study aimed to identify differentially expressed target genes influenced by T3/TR in HCC progression. Microarray profiling analysis revealed hepsin (HPN) as a potential target gene regulated by T3/TR. Quantitative reverse transcription-PCR (qRT-PCR) confirmed that T3/TR upregulates HPN expression. Promoter assays and chromatin immunoprecipitation (ChIP) analysis further demonstrated that TR directly binds to the HPN promoter region (+506/+523), activating its transcription. Functional studies showed that ectopic expression of HPN significantly inhibited cell proliferation. Furthermore, HPN was found to be involved in T3/TR-mediated suppression of cell growth by modulating the expression of CDK2 and cyclin E1. Clinically, HPN expression levels were inversely correlated with CDK2 and cyclin E1 in HCC tissues. These findings establish a novel regulatory relationship among T3/TR, HPN, CDK2, and cyclin E1, highlighting their potential role in controlling liver cancer cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.